Telix Pharmaceuticals Health Care
Biotech Canada Cancer Healthcare Medical North America Pharmaceuticals United Kingdom

$11.22 -0.22 (-1.92%)

High $11.49	Low $11.20	Trades 4,718	Turnover $7,499,551	Volume 664,557
30 June 2023 at 4:12pm

Register to track TLX and receive email alerts.

Market Cap (14-Sep) $5,324,419,584 (204th)	Close (30-Jun) $11.22 0 (0%)	Volume (30-Jun) 664,557	Shortsold (9-Sep) 35,934,087 (10.58%) (11th)
52w High $18.32	52w Low $8.26	P/E 156.25	EPS 0.14
ASX Announcements (7d) -	Twitter Mentions (7d) 0+	AFR Articles (7d) -	News Articles (7d) 2+

Short Interest

ASIC data, 9 Sep 2026

% Shorted

10.58% 0.04

vs 10.54% prior report

Most Shorted Rank

11th

of 689 shorted ASX stocks

Peak Short

16.51%

Apr 2026

Days to Cover

21.8

at 50d avg vol

View full short position history →

	Subject
	TLX TLX Ann: Telix and DuChemBio - South Korea Partnership
	1 (current) 2 3
	TLX TLX Ann: Investor Briefing on First-in-Human Translation of TLX592
	TLX TLX Ann: Approval for Ph I study of next generation product TLX592
	TLX TLX Ann: FDA Approves 68Ga-PSMA Imaging for Use at UCLA and UCSF
	TLX TLX Ann: Briefing for Investor call - TheraPharm GmbH Acquisition
	TLX TLX Ann: Acquisition of TheraPharm GmbH - Investor Call
	TLX TLX Ann: Proposed issue of Securities - TLX
	TLX TLX Ann: Telix Acquires TheraPharm GmbH
	TLX TLX Ann: Trading Halt
	TLX TLX Ann: Prostate Cancer Therapy FDA Meeting Update
	TLX TLX Ann: NDA for Prostate Cancer Imaging accepted by US FDA
	TLX TLX Ann: TLX receives EUR545k Belgian Research Grant
	TLX TLX Ann: Becoming a substantial holder
	TLX TLX Ann: App 2A quotation for shares issued in strategic transaction
	TLX TLX Ann: Appendix 3Y - change in Director interests - O Buck
	TLX TLX Ann: Cleansing Notice - issue of shares from exercise of options
	TLX TLX Ann: Appendix 2A - issue of shares on exercise of options
	TLX TLX Ann: Investor Briefing - Asia Strategy
	TLX TLX Ann: Investor Call - Strategic Licence and Commercial Partnership
	TLX TLX Ann: Appendix 3B - Proposed Issue of Securities
	TLX TLX Ann: Strategic Licence and Partnership for Greater China Market
	TLX TLX Ann: Trading Halt
	TLX TLX Ann: App 4C and Activities Report for September 2020 Quarter
	TLX TLX Ann: Licence Agmt with DKFZ for Image-Guided Prostate Surgery
	TLX TLX Ann: Completion of PhI Enrolment of Japanese Renal Cancer Study

Register to track TLX and receive email alerts.

Similar Companies

CSL

CSL

Clinuvel Pharmaceuticals

CUV

Immutep

IMM

Imugene

IMU

Mesoblast

MSB

Opthea

OPT

Paradigm Biopharmaceuticals

PAR

PYC Therapeutics

PYC

Race Oncology

RAC

End of Day Prices

Date	Close	Volume	Change
14-Sep	$16.34	4,719,870	+0.67 (4.28%)
11-Sep	$15.67	2,185,506	-1.09 (6.50%)
10-Sep	$16.76	1,751,436	+0.07 (0.42%)
09-Sep	$16.69	1,109,874	+0.19 (1.15%)
08-Sep	$16.50	1,119,678	+0.25 (1.54%)
07-Sep	$16.25	1,041,831	-0.22 (1.34%)
04-Sep	$16.47	1,525,374	+0.21 (1.29%)
03-Sep	$16.26	2,055,126	+0.57 (3.63%)
02-Sep	$15.69	1,564,041	+0.42 (2.75%)
01-Sep	$15.27	1,635,463	-0.09 (0.59%)
31-Aug	$15.36	1,047,148	-0.29 (1.85%)
28-Aug	$15.65	985,671	+0.07 (0.45%)
27-Aug	$15.58	1,267,960	+0.09 (0.58%)
26-Aug	$15.49	1,480,871	-0.67 (4.15%)
25-Aug	$16.16	989,623	0.00 (0.00%)
9 up, 5 down, and 1 flat days